Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PITALC: PITAC via videothoracoscopy for malignant pleural effusion
2025-523482-23-00Phase 2Authorised
- Sponsor
- Hospices Civils de Lyon
- Start
- Jul 2026
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cisplatin and doxorubicin in malignant pleural effusion (MPE) and pleural carcinomatosis, sponsored by Hospices Civils de Lyon. Primary endpoint: Pleural effusion recurrence at 1 month (X-ray). Planned start Jul 2026; status: authorised.
02
Drugs
cisplatindoxorubicin
03
Conditions
malignant pleural effusion (MPE)pleural carcinomatosis
Beyond the preview
Go deeper on 2025-523482-23-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-523482-23-00.